InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design
Open Access
- 25 February 2020
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 11 (4) , 1017-1027
Abstract
Introduction Suboptimal glycaemic control among people with type 1 diabetes (T1D) is known to lead to long-term micro- and macrovascular complications and, unfortunately, it is still prevalent even in the most affluent societies. Although glycated haemoglobin monitoring is considered to be the gold standard for assessing glycaemic control, such monitoring is unable to reliably measure acute glycaemic excursions. Continuous glucose monitoring (CGM) has been shown to improve glucose control and reduce the incidence of hypoglycaemia, and also allow a more complete assessment of overall glycaemic control and hyper- and hypoglycaemic excursions. The use of CGM has led to time-in-range, which is the time that a patient is within the glycaemic range of 70 to 180 mg/dL, to be adopted as a treatment target. To date, only limited data comparing the second-generation insulins glargine 300 U/mL (Gla-300) and degludec 100 U/mL (IDeg-100) in people with T1D are available, and there is no CGM literature on comparisons of the use of CGM results to assess primary, secondary and tertiary endpoints. The aim of the InRange study was to address this unmet need. Methods InRange is a multicentre, randomised, active-controlled, parallel-group, 12-week, open-label, phase 4, comparative study. Adults with T1D will be randomised to receive once-daily Gla-300 or IDeg-100 by subcutaneous injection in the morning. Following an 8-week titration period, CGM data will be collected over 20 consecutive days. Planned outcomes The primary objective is to demonstrate that Gla-300 is noninferior to IDeg-100 in terms of glycaemic control [time-in-range ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L)] and variability, as assessed using CGM, in adults with T1D. The results are expected to help confirm the utility of CGM in clinical practice in this population and provide insight into its application as an outcome measure in clinical practice. Trial registration NCT04075513. Video AbstractKeywords
Funding Information
- Sanofi, Paris, France (NCT04075513)
This publication has 25 references indexed in Scilit:
- Insulin degludec: L ower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U / mL in type 1 diabetesDiabetes, Obesity and Metabolism, 2017
- Toward Defining the Threshold Between Low and High Glucose Variability in DiabetesDiabetes Care, 2016
- Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 2016
- Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trialThe Lancet, 2016
- Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of DiabetesClinical Diabetes, 2016
- Fear of hypoglycemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for prevention - a reviewJournal of Diabetes and its Complications, 2016
- A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical RelevanceClinical Pharmacokinetics, 2014
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: OverviewDiabetes Care, 2013
- Improving the Safety of Blood Glucose MonitoringJournal of Diabetes Science and Technology, 2011
- Efficacy and safety comparison of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes. Systematic review and meta-analysisPolish Archives of Internal Medicine, 2011